Rift Valley fever virus (RVFV) is a phlebovirus that belongs to the Phenuiviridae (formerly Bunyaviridae) family of negative-sense RNA viruses. As an emerging mosquito-borne virus, the significance of RVFV is highlighted by its designation as a NIAID Category A pathogen and its inclusion on the WHO's Blueprint of Priority Diseases. Recently, the Coalition for Epidemic Preparedness Innovations (CEPI) has also included RVFV as a part of their emerging infectious diseases vaccine program, further emphasizing the potential impact of RVFV on the global health and economy. While RVFV is endemic throughout sub-Saharan Africa, competent mosquito vector species are found in North America, highlighting the potential for emergence of RVFV in non-endemic countries, including the United States. During outbreaks, RVFV causes severe disease in livestock, including sheep and cattle, which dramatically impact the socioeconomic framework in resource limited settings. Humans are spill- over hosts, where infections can result in severe consequences, including hepatic necrosis, hemorrhagic fever, encephalitis, and retinal vasculitis. Despite its significance to human health and the potential to negatively impact the socioeconomic fabric of resource-limited countries where the virus is endemic, there is a lack of safe and efficacious prophylactic and therapeutic treatment options. This gap is in part due to our lack of knowledge on host factors that contribute to RVFV infection. To address this need, we conducted a genomic screen that defined several critical factors, including a potential entry factor, which we will characterize by a multidisciplinary approach. In support, we provide compelling preliminary data, including in vitro validation in host factor sufficient and deficient cells, transcomplementation studies, direct interaction between RVFV glycoprotein Gn and the host proteins in vitro, inhibition of the entry factor by endogenous ligands in vitro in multiple cell lines from evolutionarily distinct hosts, and preliminary results of protection from RVFV infection in two conditional knock out mouse models. Importantly, we have generated many key reagents, including most cell lines and proteins, and knock-out mice supporting the feasibility. Importantly, this work will be performed by highly productive and collaborative investigators with expertise in every aspect of the proposed studies, including biochemistry, RVFV pathogenesis, immunology, proteomics, structural biology, and virology. Completion of the proposed studies will define novel host or entry factors for RVFV in target cells with tissue-specific relevance. As a specific receptor for RVFV has not previously been identified, these studies will provide important information for design of therapeutic interventions to prevent RVFV infection and disease. At the completion, we expect to fill a key gap in the field and to provide novel targets for therapeutic development.
Zoonotic viruses such as Rift Valley fever virus (RVFV) can cause rare but deadly outbreaks among domesticated animals and human populations. Our proposed work will define critical host factors for virus entry and identify novel targets that will facilitate therapeutic development. Recent outbreaks and the emerging nature of the mosquito vectors for RVFV, coupled with a rising potential of misuse in the form of bioterrorism, underscore the importance of the proposed studies to global health.
